Solasia Pharma KK (9SO) Stock Statistics & Valuation Metrics
Total Valuation
Solasia Pharma KK has a market cap or net worth of EUR 41.74M. The enterprise value is EUR 5.89B.
- Market Cap
- EUR 41.74M
- Enterprise Value
- EUR 5.89B
Share Statistics
Solasia Pharma KK has 273,414,370 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 273,414,370
- Owned by Insiders
- ―
- Owned by Institutions
- ―
Financial Efficiency
Solasia Pharma KK’s return on equity (ROE) is -0.50 and return on invested capital (ROIC) is -46.08%.
- Return on Equity (ROE)
- -0.50
- Return on Assets (ROA)
- -0.41
- Return on Invested Capital (ROIC)
- -46.08%
- Return on Capital Employed (ROCE)
- -0.47
- Revenue Per Employee
- 19.50M
- Profits Per Employee
- -39.82M
- Employee Count
- 22
- Asset Turnover
- 0.20
- Inventory Turnover
- 2.30
Valuation Ratios
The current PE Ratio of Solasia Pharma KK is -8.11. Solasia Pharma KK’s PEG ratio is -0.10.
- PE Ratio
- -8.11
- PS Ratio
- 19.00
- PB Ratio
- 5.08
- Price to FCF
- -6.47
- Price to Operating Cash Flow
- -6.47
- PEG Ratio
- -0.10
Income Statement
In the last 12 months, Solasia Pharma KK had revenue of 429.00M and earned -876.00M in profits. Earnings per share was -3.69.
- Revenue
- 429.00M
- Gross Profit
- 171.00M
- Operating Income
- -859.00M
- Pretax Income
- -876.00M
- Net Income
- -876.00M
- EBITDA
- -822.00M
- Earnings Per Share (EPS)
- -3.69
Cash Flow
In the last 12 months, operating cash flow was -1.14B and capital expenditures 0, giving a free cash flow of -1.14B billion.
- Operating Cash Flow
- -1.14B
- Free Cash Flow
- -1.14B
- Free Cash Flow per Share
- -4.18
Dividends & Yields
Solasia Pharma KK pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -15.47%
- Earnings Yield
- -12.21%
Stock Price Statistics
- Beta
- 0.88
- 52-Week Price Change
- -20.00%
- 50-Day Moving Average
- 0.14
- 200-Day Moving Average
- 0.14
- Relative Strength Index (RSI)
- 41.69
- Average Volume (3m)
- ―
Important Dates
Solasia Pharma KK upcoming earnings date is Nov 12, 2026, TBA (Not Confirmed).
- Last Earnings Date
- Aug 13, 2026
- Next Earnings Date
- Nov 12, 2026
- Ex-Dividend Date
- ―
Financial Position
Solasia Pharma KK as a current ratio of 6.06, with Debt / Equity ratio of 9.08%
- Current Ratio
- 6.06
- Quick Ratio
- 5.70
- Debt to Market Cap
- 0.01
- Net Debt to EBITDA
- 1.49
- Interest Coverage Ratio
- -61.36
Taxes
In the past 12 months, Solasia Pharma KK has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Solasia Pharma KK EV to EBITDA ratio is -7.20, with an EV/FCF ratio of -5.40.
- EV to Sales
- 15.88
- EV to EBITDA
- -7.20
- EV to Free Cash Flow
- -5.40
- EV to Operating Cash Flow
- -5.40
Balance Sheet
Solasia Pharma KK has EUR 1.29B in cash and marketable securities with EUR 78.00M in debt, giving a net cash position of EUR 1.21B billion.
- Cash & Marketable Securities
- EUR 1.29B
- Total Debt
- EUR 78.00M
- Net Cash
- EUR 1.21B
- Net Cash Per Share
- EUR 4.43
- Tangible Book Value Per Share
- EUR 5.33
Margins
Gross margin is 40.72%, with operating margin of -229.90%, and net profit margin of -231.96%.
- Gross Margin
- 40.72%
- Operating Margin
- -229.90%
- Pretax Margin
- -231.96%
- Net Profit Margin
- -231.96%
- EBITDA Margin
- -220.36%
- EBIT Margin
- -229.90%
Analyst Forecast
The average price target for Solasia Pharma KK is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- 20.47%
- EPS Growth Forecast
- 64.97%